Navigation Links
Questcor Pharmaceuticals to Be Added to S&P SmallCap 600 Index
Date:2/16/2011

ANAHEIM, Calif., Feb. 16, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that Standard & Poor's (S&P) will add the Company to the S&P SmallCap 600 Index effective after the close of the U.S. financial markets on February 17, 2011.  

"Our inclusion in the S&P SmallCap 600 Index reflects our consistent financial performance, and will serve to increase our visibility within the investment community as we continue our efforts to grow sales for H.P. Acthar® Gel for the treatment of acute exacerbations of multiple sclerosis, infantile spasms and nephrotic syndrome," said Don M. Bailey, President and CEO of Questcor.

S&P indices are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from two indications: the treatment of acute exacerbations of multiple sclerosis in adults and the treatment of infantile spasms in children under two years of age.  Questcor is also implementing plans to commercialize Acthar for use in treating nephrotic syndrome, another on-label indication. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Questcor Announces Third Quarter 2010 Earnings Release Date and Conference Call
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
4. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
5. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
6. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
7. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
8. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
9. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
10. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
11. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Amarantus BioScience Holdings, Inc. ... developing products for Regenerative Medicine, Neurology and Orphan Diseases, ... (RPDD) from the US Food and Drug Administration (FDA) ... previously granted orphan drug designation (ODD) by the US ... Holdings, Inc. (OTCQB: AMBS), a biotechnology ...
(Date:2/4/2016)... New FDA action date of July 22, 2016   ... 22, 2016   --> - New FDA ... - Lifitegrast has the potential to be the only product approved ... and symptoms of dry eye disease in adults --> - ... the U.S. in the past decade indicated for the treatment of signs and ...
(Date:2/4/2016)... Church, VA (PRWEB) , ... ... ... first-year cybersecurity conference presented by Bloomsburg University’s Digital Forensics Club, takes place ... PA. The two-day event features 20+ speakers and activities such as workshops ...
(Date:2/4/2016)... MENLO PARK, Calif. , Feb. 4, 2016 ... the "Company"), a biopharmaceutical company focused on the development and ... present at the 18 th Annual BIO CEO ... 10:00 a.m. EST in New York, NY ... CEO, will provide an update on the ongoing clinical trial ...
Breaking Biology Technology:
(Date:1/28/2016)... SYNA ), a leading developer of human interface solutions, today ... --> --> Net revenue ... to the comparable quarter last year to $470.5 million. Net income ... $0.93 per diluted share. --> ... 2016 grew 9 percent over the prior year period to $60.3 ...
(Date:1/22/2016)... January 22, 2016 ... addition of the  "Global Behavioral Biometric ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ... Behavioral Biometric Market 2016-2020"  report to ... and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ...
(Date:1/20/2016)... , Jan. 20, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... significant achievements are the result of the company,s laser ... iMedNet eClinical , it,s comprehensive, easy-to-use and highly ... --> Key MedNet growth achievements in 2015 ...
Breaking Biology News(10 mins):